Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biomea Fusion (BMEA)
NASDAQ:BMEA
Biomea Fusion (BMEA) Stock Price & Analysis
447 Followers
BMEA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.13 - $43.69
Previous Close$11.44
Volume345.54K
Average Volume (3M)1.01M
Market Cap
$383.53M
Enterprise Value$224.21M
Total Cash (Recent Filing)$199.09M
Total Debt (Recent Filing)$12.09M
Price to Earnings (P/E)-3.2
Beta-0.12
Next Earnings
May 13, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.56
Shares Outstanding35,944,584
10 Day Avg. Volume646,126
30 Day Avg. Volume1,012,339
Standard Deviation0.40
R-Squared0.00204
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)1.99
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.21
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.83
Forecast
1Y Price Target
$49.50Price Target Upside363.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Biomea Fusion News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressEncouraging preliminary data from COVALENT-101 and COVALENT-112 trials show potential efficacy of BMF-219 in blood cancers and T1D, with a well-tolerated safety profile.
Drug DevelopmentBMF-219 demonstrates promising clinical activity in T1D patients, with signs of improved β-cell function and potential long-term benefits.
Financial StabilityBiomea maintains a strong liquidity position with a significant cash reserve to support ongoing clinical trials.
Bears Say
Clinical Trial ResultsInitial BMF-219 data in the indication are from a small patient sample with differing baseline histories, lacking the context to discern clinical meaningfulness.
Financial HealthBalance sheet concerns with runway inside of 12 months and a note of going concern in the company's financial statements.
Financial PerformanceBiomea posted 1Q24 financial results with EPS of ($1.09), missing both the company's estimate of ($1.02) and the consensus of ($0.99).
---
Ownership Overview
60.04% Insiders
17.96% Mutual Funds
19.13% Other Institutional Investors
2.87% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $8.13 and its highest was $43.69 in the past 12 months.
What is Biomea Fusion’s market cap?
Currently, no data Available
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is May 13, 2024 which is in 3 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on Apr 01, 2024. The company reported -$1.09 earnings per share for the quarter, missing the consensus estimate of -$0.994 by -$0.096.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 35,944,584 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$1.09 in its last earnings report, missing expectations of -$0.994. Following the earnings report the stock price went up 2.341%.
Which hedge fund is a major shareholder of Biomea Fusion?
Among the largest hedge funds holding Biomea Fusion’s share is Baker Bros Advisors LP. It holds Biomea Fusion’s shares valued at 31M.
---
Biomea Fusion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.50 (363.92% Upside)
$49.50 (363.92% Upside)
Blogger Sentiment
Bullish
BMEA Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 301.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.09%
12-Months-Change
Fundamentals
Return on Equity
-116.52%
Trailing 12-Months
Asset Growth
49.59%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companies lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
---
BMEA Stock 12 Month Forecast
Average Price Target
$49.50
▲(363.92% Upside)
Technical Analysis
Best Analysts Covering BMEA
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
+30.96%
assigned a buy rating 2 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +30.96% per trade.
---